entertainment -WSS

entertainment

author：entertainment 2025-09-14 11:48:35 - browse：255

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Study points to new risk in gene therapy death of Terry Horgan

knowledge

hotspot

WSS

Experts study whether long Covid risk adds up with each reinfection

What we owe ALS patients — and why one company fell short

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

The Karikó problem: Lessons for funding basic research

CRISPR base editing slashes cholesterol levels in monkeys

RSV injection headlines need to be accurate for good uptake

leisure time

entertainment

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

WHO recommends second malaria vaccine

Anesthesiologist group: stop taking Ozempic before surgery

RSV injection headlines need to be accurate for good uptake

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Medical leaders decry Supreme Court decision on affirmative action

Lawsuit highlights wrinkle for disputes over surprise medical bills

Activists slam private health insurers over coverage restrictions

RSV injection headlines need to be accurate for good uptake

explore

AbbVie dramatically boosts its spending on lobbying

What we owe ALS patients — and why one company fell short

FDA official pushes for dedicated emerging pathogens team

What to know about Saharan dust affecting the US and how it can affect health

The biotech scorecard for Q4: 16 stock

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

Wikipedia

hotspot

explore